Connect with us

Marijuana Stocks

Valens Added to The New York Stock Exchange-Traded The Cannabis ETF (THCX)

Arina P



Valens Added to The New York Stock Exchange-Traded The Cannabis ETF (THCX)

Valens Grow Works Corp. has been added to The Cannabis ETF which trades on the New York Stock Exchange. Valens is a provider of extraction products and services using diverse extraction methodologies, delivery formats, and laboratories. Now being a part of The Cannabis ETF, it provides further opportunities to expand and increase the profile among investors in the US. Investors are looking for value and have found this in Valens as their business grows internationally.

THCX follows the Innovation Labs Cannabis Index – a modified market capitalization index with a portfolio of 36 stocks that are expected to benefit from the growth of legalization. Valens is part of THCX’s expansion which includes a variety of cannabis industry subthemes. Many combine science and technology and were created to appeal to investors looking for differentiation outside of traditional seed-to-sale. The index rebalances on a monthly basis and is now considered the lowest cost US-listed cannabis ETF that is passively managed.

Arina has a Master’s degree in Business and lives in Sydney, Australia and is one of our top contributors as a postgraduate qualified writer. While being a Member Of The Appraisal Institute, she focuses her writing efforts on health, home, business, technology and now cannabis/cbd here.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Join Us On Facebook


Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?